Lung Cancer

Metformin appeared to increase glucose uptake in lung cancer cells, according to results from a phase II trial.

The study found patients with lung cancer referred to palliative care earlier lived longer.

The findings of a new study presented at ESMO may offer a new treatment for non–small cell lung cancer.

Researchers examined how metformin and TKI therapy did in combatting lung cancer.

Several promising drugs for the treatment of lung cancer have been garnering attention over recent years. These new treatments have been highlighted at conferences and are sure to impact the standard of care.

A new study presented at the International Association for the Study of Lung Cancer's 2019 conference may have found a model for lung cancer screening which improves on lung cancer screening guidelines from the U.S. Preventive Services Task Force.

A new study shows patients with advanced non­­­­–small-cell lung cancer have preferences on which chemotherapy side effects they'd prefer to avoid which highlights the importance of incorporating patient preferences into treatment.

In this phase III trial, investigators assessed the clinical efficacy and safety of durvalumab with or without tremelimumab with etoposide and carboplatin or cisplatin chemotherapy followed by durvalumab with or without tremelimumab maintenance therapy compared with EP alone as first-line treatment in extensive-stage small-cell lung cancer.

Video-assisted thoracic surgery (VATS) results in fewer in-hospital complications and a shorter length of stay compared with open surgery in patients with early-stage lung cancer.

In a phase I trial, researchers demonstrated that KRAS inhibitor AMG 510 demonstrated safety and antitumor activity in advanced NSCLC patients.

Combination immunotherapy with nivolumab plus ipilimumab was examined as a first-line therapy for patients with advanced non–small-cell lung cancer. Results were presented at the International Associate for the Study of Lung Cancer 2019 World Conference on Lung Cancer.

Data presented at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer suggested tumor mutational burden may not be associated with the efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy.

Little research has been done on these complications commonly found in lung cancer.

Researchers focused on a subset of patients with high tumor mutational burden using a 20-mutation-per-megabase threshold and found significant improvement in progression-free survival and overall survival.

Findings from the upcoming International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer show camrelizumab and chemotherapy showed survival benefits for patients with metastatic or otherwise advanced non-squamous non–small-cell lung cancer.

What is the best treatment option after progression to chemotherapy/immunotherapy (chemo/IO) as first-line treatment for PD-L1–positive lung adenocarcinoma with no sensitizing mutations?

A new meta-analysis compared survival in patients with advanced non–small cell lung cancer who received immunotherapy vs those who received chemotherapy.

A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer.

Researchers tried using deep machine learning to anticipate disease outcomes and progression in patients with lung cancer.

In elderly patients with brain metastasis secondary to small cell lung cancer, whole brain radiation therapy was linked to a modest rise in survival. 

Throughout the last half of the 20th century, despite enormous research efforts, lung cancer remained the most feared as well as lethal cancer across the world. Efforts to update screening management are attempting to change that.

A new study examined whether stereotactic body radiotherapy prior to pembrolizumab improved response rate in lung cancer patients.

A new analysis suggests more people may benefit from more inclusive lung cancer screening guidelines.

Researchers tested the MET inhibitor capmatinib in patients with non–small-cell lung cancer and a MET exon 14 skipping mutation.

Lurbinectedin may represent a new treatment option as second-line therapy for patients with small-cell lung cancer.

A study in the Journal of the National Cancer Institute evaluated responses in men vs women to combination chemotherapy and a PD-1 or PD-L1 inhibitor.

The FDA approved pembrolizumab as a treatment option for patients with metastatic small-cell lung cancer.

Cancer Network spoke with Karen L. Reckamp, MD, of City of Hope, about the link between several gene mutations and lung cancer in smokers vs nonsmokers.

Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan.